# Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

> **NCT06149481** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Retifanlimab
- **BIOLOGICAL:** Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
- **DRUG:** N-803
- **DRUG:** SX-682

## Key facts

- **NCT ID:** NCT06149481
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-26
- **Primary completion:** 2027-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06149481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06149481, "Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06149481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*